Clinical Trial Update: Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of Celecoxib in combination with Oxaliplatin and Capecitabine for gastric cancer and gastroesophageal junction cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Celecoxib (Celecoxib)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: University of California, Irvine | Conditions: Gastric Carcinoma, Gastroesophageal Junction Carcinoma | Phase 2 | Status: TERMINATED